Literature DB >> 11864998

Clinically useful monoclonal antibodies in treatment.

E Drewe1, R J Powell.   

Abstract

Monoclonal antibodies have been used in clinical diagnosis for many years but it is only now that these agents are being licensed for clinical treatments. This review will focus on UK licensed monoclonal antibodies highlighting their clinical benefits, limitations, and side effects.

Mesh：

Substances：

Year:  2002        PMID： 11864998      PMCID： PMC1769580          DOI： 10.1136/jcp.55.2.81

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN： 0021-9746            Impact factor:   3.411


  59 in total

1.  An engineered human antibody to TNF (CDP571) for active Crohn's disease: a randomized double-blind placebo-controlled trial.

Authors:  W J Sandborn; B G Feagan; S B Hanauer; D H Present; L R Sutherland; M A Kamm; D C Wolf; J P Baker; C Hawkey; A Archambault; C N Bernstein; C Novak; P K Heath; S R Targan
Journal:  Gastroenterology       Date:  2001-05       Impact factor: 22.682

Review 2.  General aspects of cytokine-release syndrome: timing and incidence of symptoms.

Authors:  D R Jeyarajah; J R Thistlethwaite
Journal:  Transplant Proc       Date:  1993-04       Impact factor: 1.066

3.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.

Authors:  D J Slamon; G M Clark; S G Wong; W J Levin; A Ullrich; W L McGuire
Journal:  Science       Date:  1987-01-09       Impact factor: 47.728

4.  Follicular lymphoma: prognostic factors for response and survival.

Authors:  C J Gallagher; W M Gregory; A E Jones; A G Stansfeld; M A Richards; H S Dhaliwal; J S Malpas; T A Lister
Journal:  J Clin Oncol       Date:  1986-10       Impact factor: 44.544

5.  Humanised monoclonal antibody therapy for rheumatoid arthritis.

Authors:  J D Isaacs; R A Watts; B L Hazleman; G Hale; M T Keogan; S P Cobbold; H Waldmann
Journal:  Lancet       Date:  1992-09-26       Impact factor: 79.321

6.  Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20.

Authors:  M E Reff; K Carner; K S Chambers; P C Chinn; J E Leonard; R Raab; R A Newman; N Hanna; D R Anderson
Journal:  Blood       Date:  1994-01-15       Impact factor: 22.113

7.  Risk factors for chronic rejection in renal allograft recipients.

Authors:  P S Almond; A Matas; K Gillingham; D L Dunn; W D Payne; P Gores; R Gruessner; J S Najarian
Journal:  Transplantation       Date:  1993-04       Impact factor: 4.939

8.  Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group.

Authors:  E J Ziegler; C J Fisher; C L Sprung; R C Straube; J C Sadoff; G E Foulke; C H Wortel; M P Fink; R P Dellinger; N N Teng
Journal:  N Engl J Med       Date:  1991-02-14       Impact factor: 91.245

9.  Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. The Respiratory Syncytial Virus Immune Globulin Study Group.

Authors:  J R Groothuis; E A Simoes; M J Levin; C B Hall; C E Long; W J Rodriguez; J Arrobio; H C Meissner; D R Fulton; R C Welliver
Journal:  N Engl J Med       Date:  1993-11-18       Impact factor: 91.245

10.  Reduction of acute renal allograft rejection by daclizumab. Daclizumab Double Therapy Study Group.

Authors:  B Nashan; S Light; I R Hardie; A Lin; J R Johnson
Journal:  Transplantation       Date:  1999-01-15       Impact factor: 4.939
View more
  8 in total

1.  Purification of monoclonal antibodies from clarified cell culture fluid using Protein A capture continuous countercurrent tangential chromatography.

Authors:  Amit K Dutta; Travis Tran; Boris Napadensky; Achyuta Teella; Gary Brookhart; Philip A Ropp; Ada W Zhang; Andrew D Tustian; Andrew L Zydney; Oleg Shinkazh
Journal:  J Biotechnol       Date:  2015-03-05       Impact factor: 3.307

Review 2.  Lowering serum lipids via PCSK9-targeting drugs: current advances and future perspectives.

Authors:  Ni-Ya He; Qing Li; Chun-Yan Wu; Zhong Ren; Ya Gao; Li-Hong Pan; Mei-Mei Wang; Hong-Yan Wen; Zhi-Sheng Jiang; Zhi-Han Tang; Lu-Shan Liu
Journal:  Acta Pharmacol Sin       Date:  2017-01-23       Impact factor: 6.150

3.  Autoimmune hepatitis: new paradigms in the pathogenesis, diagnosis, and management.

Authors:  Ye H Oo; Stefan G Hubscher; David H Adams
Journal:  Hepatol Int       Date:  2010-05-19       Impact factor: 6.047

Review 4.  Post-exposure treatments for Ebola and Marburg virus infections.

Authors:  Robert W Cross; Chad E Mire; Heinz Feldmann; Thomas W Geisbert
Journal:  Nat Rev Drug Discov       Date:  2018-01-29       Impact factor: 84.694

5.  The novel S59P mutation in the TNFRSF1A gene identified in an adult onset TNF receptor associated periodic syndrome (TRAPS) constitutively activates NF-κB pathway.

Authors:  Eliana Greco; Ada Aita; Paola Galozzi; Alessandra Gava; Paolo Sfriso; Ola H Negm; Patrick Tighe; Francesco Caso; Filippo Navaglia; Emanuela Dazzo; Marzia De Bortoli; Alessandra Rampazzo; Laura Obici; Simona Donadei; Giampaolo Merlini; Mario Plebani; Ian Todd; Daniela Basso; Leonardo Punzi
Journal:  Arthritis Res Ther       Date:  2015-04-03       Impact factor: 5.156

Review 6.  A current perspective on applications of macrocyclic-peptide-based high-affinity ligands.

Authors:  Daniël Leenheer; Peter Ten Dijke; Christopher John Hipolito
Journal:  Biopolymers       Date:  2016-11       Impact factor: 2.505

7.  gC1qR/HABP1/p32 Is a Potential New Therapeutic Target Against Mesothelioma.

Authors:  Ellinor Peerschke; Kenneth Stier; Xiaoyu Li; Evelyn Kandov; Elisa de Stanchina; Qing Chang; Yuquan Xiong; Katia Manova-Todorova; Ning Fan; Afsar Barlas; Berhane Ghebrehiwet; Prasad S Adusumilli
Journal:  Front Oncol       Date:  2020-08-12       Impact factor: 6.244

8.  Isolation and light chain shuffling of a Plasmodium falciparum AMA1-specific human monoclonal antibody with growth inhibitory activity.

Authors:  Melanie Seidel-Greven; Otchere Addai-Mensah; Holger Spiegel; Gwladys Nina Chiegoua Dipah; Stefan Schmitz; Gudrun Breuer; Margaret Frempong; Andreas Reimann; Torsten Klockenbring; Rainer Fischer; Stefan Barth; Rolf Fendel
Journal:  Malar J       Date:  2021-01-11       Impact factor: 2.979
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.